OBJECTIVES: To report long-term HIV treatment outcomes in 7 Caribbean countries. DESIGN: Observational cohort study. METHODS: We report outcomes for all antiretroviral therapy (ART) naive adult patients enrolled on ART from program inception until study closing for cohorts in Barbados, the Dominican Republic, Haiti, Jamaica, Martinique, Trinidad, and Puerto Rico. Incidence and predictors of mortality were analyzed by time-to-event approaches. RESULTS: A total of 8203 patients were on ART from 1998 to 2008. Median follow-up time was 31 months (interquartile range: 14-50 months). The overall mortality was 13%: 6% in Martinique, 8% in Jamaica, 11% in Trinidad, 13% in Haiti, 15% in the Dominican Republic, 15% in Barbados, and 24% in Puerto Rico. Mortality was associated with male gender [hazard ratio (HR), 1.58; 95% confidence interval (CI): 1.33 to 1.87], body weight (HR, 0.85 per 10 pounds; 95% CI: 0.82 to 0.89), hemoglobin (HR, 0.84 per g/dL; 95% CI: 0.80 to 0.88), CD4 cell count (0.90 per 50 CD4 cells; 95% CI: 0.86 to 0.93), concurrent tuberculosis (HR, 1.58; 95% CI: 1.25 to 2.01) and age (HR, 1.19 per 10 years; 95% CI: 1.11 to 1.28). After controlling for these variables, mortality in Martinique, Jamaica, Trinidad, and Haiti was not significantly different. A total of 75% of patients remained alive and in care at the end of the study period. CONCLUSIONS: Long-term mortality rates vary widely across the Caribbean countries. Much of the difference can be explained by disease severity at ART initiation, nutritional status, and concurrent tuberculosis. Earlier ART initiation will be critical to improve the outcomes.
OBJECTIVES: To report long-term HIV treatment outcomes in 7 Caribbean countries. DESIGN: Observational cohort study. METHODS: We report outcomes for all antiretroviral therapy (ART) naive adult patients enrolled on ART from program inception until study closing for cohorts in Barbados, the Dominican Republic, Haiti, Jamaica, Martinique, Trinidad, and Puerto Rico. Incidence and predictors of mortality were analyzed by time-to-event approaches. RESULTS: A total of 8203 patients were on ART from 1998 to 2008. Median follow-up time was 31 months (interquartile range: 14-50 months). The overall mortality was 13%: 6% in Martinique, 8% in Jamaica, 11% in Trinidad, 13% in Haiti, 15% in the Dominican Republic, 15% in Barbados, and 24% in Puerto Rico. Mortality was associated with male gender [hazard ratio (HR), 1.58; 95% confidence interval (CI): 1.33 to 1.87], body weight (HR, 0.85 per 10 pounds; 95% CI: 0.82 to 0.89), hemoglobin (HR, 0.84 per g/dL; 95% CI: 0.80 to 0.88), CD4 cell count (0.90 per 50 CD4 cells; 95% CI: 0.86 to 0.93), concurrent tuberculosis (HR, 1.58; 95% CI: 1.25 to 2.01) and age (HR, 1.19 per 10 years; 95% CI: 1.11 to 1.28). After controlling for these variables, mortality in Martinique, Jamaica, Trinidad, and Haiti was not significantly different. A total of 75% of patients remained alive and in care at the end of the study period. CONCLUSIONS: Long-term mortality rates vary widely across the Caribbean countries. Much of the difference can be explained by disease severity at ART initiation, nutritional status, and concurrent tuberculosis. Earlier ART initiation will be critical to improve the outcomes.
Authors: Didier K Ekouevi; Eric Balestre; Franck-Olivier Ba-Gomis; Serge Paul Eholie; Moussa Maiga; Clarisse Amani-Bosse; Albert Minga; Eugène Messou; Papa Salif Sow; Charlotte Lewden; Hamar Allassane Traoré; Emmanuel Bissagnene; François Dabis Journal: Trop Med Int Health Date: 2010-06 Impact factor: 2.622
Authors: Mette V Larsen; Lars H Omland; Jan Gerstoft; Carsten S Larsen; Janne Jensen; Niels Obel; Gitte Kronborg Journal: Addiction Date: 2010-03 Impact factor: 6.526
Authors: Claudia Hawkins; Guerino Chalamilla; James Okuma; Donna Spiegelman; Ellen Hertzmark; Eric Aris; Tarcila Ewald; Ferdinand Mugusi; Deo Mtasiwa; Wafaie Fawzi Journal: AIDS Date: 2011-06-01 Impact factor: 4.177
Authors: Margaret May; Andrew Boulle; Sam Phiri; Eugene Messou; Landon Myer; Robin Wood; Olivia Keiser; Jonathan A C Sterne; Francois Dabis; Matthias Egger Journal: Lancet Date: 2010-07-15 Impact factor: 79.321
Authors: Andrew Boulle; Gilles Van Cutsem; Katherine Hilderbrand; Carol Cragg; Musaed Abrahams; Shaheed Mathee; Nathan Ford; Louise Knight; Meg Osler; Jonny Myers; Eric Goemaere; David Coetzee; Gary Maartens Journal: AIDS Date: 2010-02-20 Impact factor: 4.177
Authors: Doris V Báez-Feliciano; Rafael Quintana; María A Gómez; Diana M Fernández; Miriam Velázquez; Eddy Olivares; Carlos León Valiente; Angel M Mayor; Robert F Hunter-Mellado Journal: Bol Asoc Med P R Date: 2006 Jul-Sep
Authors: Rishikesh P Dalal; Catherine Macphail; Mmabatho Mqhayi; Jeff Wing; Charles Feldman; Matthew F Chersich; Willem D F Venter Journal: J Acquir Immune Defic Syndr Date: 2008-01-01 Impact factor: 3.731
Authors: Suely H Tuboi; Mauro Schechter; Catherine C McGowan; Carina Cesar; Alejandro Krolewiecki; Pedro Cahn; Marcelo Wolff; Jean W Pape; Denis Padgett; Juan Sierra Madero; Eduardo Gotuzzo; Daniel R Masys; Bryan E Shepherd Journal: J Acquir Immune Defic Syndr Date: 2009-08-15 Impact factor: 3.731
Authors: Nancy H Puttkammer; Steven B Zeliadt; Janet G Baseman; Rodney Destiné; Jean Wysler Domerçant; Nancy Rachel Labbé Coq; Nernst Atwood Raphael; Kenneth Sherr; Mary Tegger; Krista Yuhas; Scott Barnhart Journal: Rev Panam Salud Publica Date: 2014-10